Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 5/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28039648 | 0.98 | ALDH1A1 (0.49) | ALDH1A1KDM4EMCHR1SMN1; SMN2JAK2 | |
| SCHEMBL18181668 | 0.85 | ALK (0.46) | ALDH1A1KDM4ESMN1; SMN2NQO2PIN1 | |
| SCHEMBL7747283 | 0.80 | MCHR1 (0.51) | ALDH1A1MCHR1JAK2JAK1TYK2 | |
| SCHEMBL18181674 | 0.79 | ALK (0.47) | ALDH1A1KDM4ESMN1; SMN2HPGDS | |
| SCHEMBL18181671 | 0.79 | ALK (0.45) | ALDH1A1KDM4ESMN1; SMN2JAK2JAK3 | |
| SCHEMBL1039857 | 0.79 | MCHR1 (0.59) | ALDH1A1KDM4EMCHR1JAK2JAK1 | |
| SCHEMBL13313220 | 0.79 | MCHR1 (0.50) | ALDH1A1MCHR1SMN1; SMN2JAK2JAK1 | |
| SCHEMBL1633206 | 0.79 | HPGDS (0.50) | ALDH1A1KDM4EMCHR1JAK2JAK1 | |
| SCHEMBL31172952 | 0.78 | PIN1 (0.47) | ALDH1A1KDM4ESMN1; SMN2PIN1NPC1 | |
| SCHEMBL13439479 | 0.77 | MCHR1 (0.49) | ALDH1A1KDM4EMCHR1SMN1; SMN2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968360-A | Quinazoline compound and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250092017-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4450495-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | Suzhou Puhe Biopharma Co., Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024131938-A1 | QUINAZOLINE COMPOUND AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2023161844-A1 | USE OF HPK1 INHIBITOR IN TREATMENT OF INTERFERON-RELATED DISEASES | 智宠制药（北京）有限公司 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023143135-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514728-A | Quinazoline derivative and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116478136-A | 2-piperidinyl or 2-pyrazolyl substituted pyrimidine compounds as EGFR inhibitors | 苏州浦合医药科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023134266-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | 苏州浦合医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134266-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | 苏州浦合医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092017-A1 | 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ALDH1A1 3675/4885KDM4E 4442/4885MCHR1 4458/4885 |
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | ALDH1A1 634/4885KDM4E 3333/4885MCHR1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.